Kornimate/medical-research-clean huggingface dataset:
rapid profiling of bone marrow, at presentation and after 5 days of induction therapy

Conditions: AML

Summary: personalization of aml therapy, require a reliable mechanism for accurate characterization of patient specific leukemia phenotype and genotype. patient's specific leukemic phenotype or in practical clinical term, patient's leukemia sensitivity to induction therapy, should best investigated in-vivo during induction. elimination of circulating leukemic blasts from peripheral blood by day 5 was shown to discriminate between good responders with superior long term survival and poor responders with poor outcome. however, many aml patients have no circulating blasts at diagnosis and even in those who have, elimination rate of it from peripheral blood was never correlated with actual response in bone marrow. currently, the only available source for patient's specific leukemia profile, is the bone marrow sample at diagnosis. since leukemic blasts are heterogeneous and come from multiple different clones, "on diagnosis" marrow consist a spectrum of chemotherapy sensitive and resistance clones. clones may vary by their molecular abnormalities and results from "on diagnosis" marrow may overlook minor resistant but existing clones. long term prognosis is determined by those resistant clones and though our interests should be focused into the abnormalities of these clones. residual blasts on day 5 marrow may better represent the profile of patient's leukemic resistant clones.


Eligibility criteria:
inclusion criteria: * diagnosis of acute myeloid leukemia other than apl * age \> 18 * patient's considered by their physician "fit" for intensive induction therapy exclusion criteria: * withdrawal of informed consent or inability to consent * previous allogeneic transplantation. * one of the following lab values persistent from presentation to day 5: * serum creatinine \> 2mg/dl, direct bilirubin \> 2mg/dl * sgot (ast) \> x4 upper limit of normal * left ventricular ejection fraction \< 40% as assessed 2-d echocardiogram * coagulation abnormalities (inr \> 1.6, ptt \> x1.5 normal range)

Keywords: aml induction
stapled transanal rectal resection (starr) with contour® transtartm

Conditions: Obstructed Defecation Syndrome; Rectocele; Intussusception; SNS

Summary: the stapled transanal rectal resection (starr procedure) is an effective treatment for obstructed defecation syndrome (ods) caused by intussusception and rectocele. recently a new technique has been developed using the new contour® transtartm stapler, which was specifically designed to facilitate the starr procedure. the investigators would like to evaluate the morbidity and quality of life.


Eligibility criteria:
inclusion criteria: * rectocele * intussusception exclusion criteria: * non operability * inflammatory bowel disease

Keywords: obstructed defecation syndrome ods rectocele intussusception starr
tryptophan supplementation to improve night shift workers' health

Conditions: Sleep; Mood; Burnout; Melatonin Deficiency; Cortisol Deficiency

Summary: this randomized cross-over double-blinded trial aims to investigate the health effect of oral l-tryptophan supplementation on workers who rotate night shift work, and to examine the influences of different frequencies and timings of supplementation on the health effects.

this study aims to investigate the health effect of oral l-tryptophan supplementation on workers who rotate night shift work, and to examine the influences of different frequencies and timings of supplementation on the health effects. night shift work affects melatonin and cortisol variation, insomnia, mood issues, and metabolic syndrome. short-term tryptophan supplementation was shown to improve melatonin, sleep quality, and cortisol response to acute stress. little is known whether a longer term of longer-term tryptophan supplementation would alleviate the health impacts of night shift work. nevertheless, melatonin and cortisol have their normal circadian patterns. nothing is known about what temporal structure of tryptophan supplement would maximize its health effects on night shift workers melatonin and cortisol levels. we will conduct a double-blind cross-over randomized controlled trial to examine the benefits of oral tryptophan administration (3g/day, t.i.d.) on night shift workers' health outcomes: melatonin and cortisol levels, sleep quality, moods and work performance. we expect to reveal the health effect of tryptophan supplementation in night shift workers by using sophisticated study design.

Eligibility criteria:
inclusion criteria: * age: adults \>=20 y/o * adults who had night shift schedule \>1 month before enrollment, and will have similar night shift schedule in the following 2 months. (eligible night shift schedule: \>1 day of evening or night shift in a week) * people who will not have plans to travel to another time zone in the following 2-3 months * people who will plan to stay in the same job position for the following 3 months * people who have no experience in taking tryptophan or melatonin supplement in the past month * body weight \>= 50kg and \<=80kg * non-pregnant, non-breastfeeding, not taking contraceptives * not under treatment of steroids, not taking sleeping pills exclusion criteria: * diagnosis of renal or liver diseases * diagnosis of cushing's disease, addison's disease * psychiatric diagnosis, such as depression and anxiety disorders * neurological diseases such as dementia, epilepsy, parkinson's disease

Keywords: tryptophan shift work randomized trial melatonin cortisol
safety and efficacy study of photopheresis with uvadex to prevent graft-versus-host disease

Conditions: Graft-versus-Host Disease

Summary: the purpose of this study is to determine whether extracorporeal photopheresis with uvadex (ecp) prior to bone marrow or peripheral blood stem cell transplantation is effective in the prevention of graft-versus-host disease (gvhd).

approximately 30% of hla-identical related bone marrow graft recipients and up to 90% of patients receiving bone marrow from unrelated donors develop significant acute gvhd despite the use of prophylactic therapies such as cyclosporine and methotrexate. about half of these patients respond to initial treatment with steroids and require no further treatment. the remainder of these patients are either unresponsive to initial therapy or become steroid-resistant over time. the prognosis in these cases is poor and mortality for patients with steroid-resistant gvhd may be as high as 50%. ecp is a technique in which peripheral white blood cells are exposed to a photoactivatable compound (uvadex) administered extracorporeally and ultraviolet a light. after cells are reinfused into the patient, their function is altered, thereby activating mechanisms that allow for further regulation of specific lymphocyte populations. ecp has shown activity in several inflammatory and autoimmune diseases, including scleroderma, rheumatoid arthritis, transplantation rejection, acute and chronic gvhd. in a previous single-center, open label, single-arm study of 56 patients receiving ecp treatment on two consecutive days and reduced-intensity bone-marrow conditioning prior to bone marrow transplantation from matched or partially matched human donors, the incidence of grade ii-iv acute gvhd was less than 10%. this is in contrast to an expected incidence of approximately 40%. the purpose of this study is to determine the role of ecp, administered pre-transplant, in preventing gvhd when used in conjunction with a standard myeloablative conditioning regimen.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of a malignancy of the blood (e.g. leukemia) for which allogeneic bone marrow or peripheral blood stem cell transplantation is a treatment option. * patients who are candidates for a standard allogenic bone marrow transplant or pbsc transplant. * patients must have adequate renal, hepatic, pulmonary and cardiac function to enable the patient to tolerate shifts in the volumes of body fluids associated with extracorporeal photopheresis, as determined by the physician's clinical judgement. * patients must weigh at least 40 kg (88 lbs) exclusion criteria: * patients who have received a prior bone marrow transplant or peripheral blood stem cell transplant.

Keywords: extracorporeal photopheresis graft-versus-host disease
pharmacokinetic study of fondaparinux in outpatients with renal dysfunction

Conditions: Kidney Diseases

Summary: to determine the appropriate dose and safety of a preventative dose of fondaparinux, an anticoagulant medication (blood thinner) in patients with kidney disease.

this study will evaluate the pk of fondaparinux in patients who have renal insufficiency. fondaparinux is cleared from the body mainly by the kidneys. therefore in patients with kidney diseases, full doses of fondaparinux could cause bleeding problems. the correct dose of fondaparinux that should be used in patients with kidney disease is not known. the purpose of this research is to determine the pk and safety of a preventative dose (2.5mg subcutaneously every other day) of fondaparinux for patients with kidney disease.

Eligibility criteria:
inclusion criteria: * outpatients in the medicine and nephrology clinics who are 18 years or older, * outpatients in the medicine and nephrology clinics who have an estimated creatinine clearances between 20-30ml/min, * outpatients in the medicine and nephrology clinics who are able to give consent will be included. exclusion criteria: * anticoagulation therapy for thrombosis or other indication * pregnant or breast-feeding * hypersensitivity to fondaparinux * subjects also will be excluded if there is concern for an increased risk of bleeding which includes the following: * known bleeding disorder (see section 8. hemostatic assessment) * blood transfusion in the past 3 months * acute ulcer disease with past 3 months * platelet count \< 120,000 mm3 * prolonged baseline prothrombin time (pt) or activated partial thromboplastin time (aptt) above upper limit of normal laboratory range * major trauma or surgery within two weeks prior to enrollment * history of intracranial hemorrhage

Keywords: fondaparinux pharmacokinetic
immobilization after an anterior glenohumeral joint dislocation with a bankart lesion

Conditions: Glenohumeral Joint Dislocation

Summary: glenohumeral joint dislocation is the most frequent joint dislocation with a prevalence of 1.7/100000 citizens/year. it is treated by reduction, under sedation or anaesthesia, followed by an immobilization of the arm. the purpose of the study is to evaluate the healing of the labrum in first time anterior glenohumeral joint dislocation with a bankart lesion in young patients by comparing an external rotation brace to an internal rotation brace to immobilize the injured arm.


Eligibility criteria:
inclusion criteria: * \> 18 years old * \< 40 years old * anterior glenohumeral joint dislocation proved by radiography * dislocation needing a reduction manoeuvre * home close to evaluation site for 24 months follow-up visits * signed consent form exclusion criteria: * associated fracture * hill-sachs lesion = or \> than 30% * neurovascular deficit * hypermobility * pre-existing instability of the injured shoulder * systemic neurological disease * allergy to gadolinium * functional sequel to the shoulder due to previous injury * incapacitated adult patient * minor patient * home far from evaluation site * refusal to sign the consent form
xience xpedition/alpine/sierra in routine clinical practice

Conditions: Percutaneous Transluminal Coronary Angioplasty; Coronary Artery Disease

Summary: the purpose of this study is to evaluate effectiveness and safety of xience xpedition/alpine/sierra in routine clinical practice


Eligibility criteria:
inclusion criteria: * age 19 and more * intervention with xience xpedition or alpine or sierra everolimus eluting coronary stent * agreed with written informed consent form exclusion criteria: * intervention with xience xpedition or alpine or sierra everolimus eluting coronary stent and other drug eluting stent at the same time * life expectancy of 1year and under * cardiac shock

Keywords: xience xpedition routine clinical practice alpine sierra
geniculate artery embolization for treatment of osteoarthritis

Conditions: Osteoarthritis

Summary: single-arm, single-center, no sham or placebo, prospective pilot trial designed to evaluate the feasibility and safety of transcatheter arterial embolization in patients with mild to moderate radiographic knee oa. eligible participants will receive geniculate artery embolization using embozene™ color-advanced microspheres. patients will be followed up for a total of 12 months.

the current study seeks to determine whether transcatheter arterial embolization of abnormal neovasculature arising from the genicular arterial branches is safe and effective in the treatment of mild-to-moderate knee oa.

Eligibility criteria:
inclusion criteria: 1. 30-80 years of age of any gender; 2. kellgren-lawrence grade 2, 3, or 4 (in select subjects who have no bony deformity) knee oa on most recent knee radiograph obtained within 6 months of screening visit; 3. knee pain resistant to conservative treatment for at least 3 months (anti- inflammatory drugs, acetaminophen, physical therapy, muscle strengthening, or intra- articular injection of hyaluronic acid and/or steroids); 4. moderate to severe knee pain: pain vas ≥ 40 mm with 0 representing 'no pain' and 100 'the worst pain imaginable. if both knees meet inclusion criteria, the one with a higher vas score will be chosen for the study (i.e., target knee). 5. willing, able, and mentally competent to provide informed consent and complete study questionnaires in english. the study questionnaire is validated in english. exclusion criteria: 1. active systemic or local knee infection; 2. active malignancy; 3. life expectancy less than 12 months; 4. prior ipsilateral knee surgery (within 3 years of baseline visit), arthroscopic surgery (within 6 months of baseline), total or partial knee replacement regardless of timing; 5. ipsilateral knee intra-articular injection in the last 3 months; 6. rheumatoid arthritis, spondyloarthropathies, crystal disease, gout, pseudogout, or lupus; 7. pregnant during the study period; 8. renal dysfunction as defined by serum creatinine \>1.6 dl/mg or egfr \<60 on blood tests obtained within 30 days of procedure; 9. body weight greater than 200 kg; 10. uncorrectable coagulopathy (platelet count \ 1.5 within 30 days of procedure; 11. known history of contrast allergy resulting in anaphylaxis; 12. known significant arterial atherosclerosis that would limit selective angiography and/or lower extremity symptoms thought to be secondary to arterial vascular disease (eg claudication, ischemic rest pain); 13. post-traumatic knee (if trauma occurred within 12 months of baseline or was associated with fractures); 14. known avascular necrosis in the target knee; 15. contraindications to mri such as such as claustrophobia, metallic fragment/implants, pacemaker.
assessing the fit of motivational interviewing by cultures with adolescents

Conditions: Alcoholism

Summary: hispanic adolescents experience more severe alcohol-related consequences due to their alcohol abuse and yet significantly fewer hispanic adolescents receive alcohol treatment, particularly among justice-involved youth. despite the level of research that has been conducted on motivational interviewing (mi) with mainstream samples, no published studies have investigated the efficacy of this brief, individual intervention with hispanic adolescents. the overarching objective of this application is to evaluate the efficacy of a brief individual intervention (mi) for problem drinking behaviors with a sample of justice-involved hispanic and caucasian adolescents to determine if this intervention is differentially effective between hispanic and caucasian adolescents. specifically, the first aim is to determine whether an mi intervention targeting alcohol abuse is effective at reducing alcohol use and related risk behavior in a sample of adolescent alcohol abusers. the second aim is to examine whether the effects of mi on problem drinking outcomes (e.g., alcohol problems, quantity of drinking, frequency of binging) are different between hispanic versus caucasian adolescents. because it is important to determine the mechanisms that mediate the effects of mi and determine whether these mechanisms differ between caucasian and hispanic adolescents, the third aim is to examine whether group (hispanic vs. caucasian) moderates the mediational linkages in the overall model using a cross-groups approach to moderated mediation. to accomplish these aims, 453 caucasian and hispanic justice-involved alcohol abusing adolescents (ages 14-17) will be randomized to either two 60 minute mi interventions (one at baseline and a second, one week later) or an education condition. all adolescents will receive behavioral assessments at baseline, 3, 6 and 12 months. the proposed research is expected to take a significant step towards reducing current racial/ethnic health disparities in alcohol treatment for hispanic adolescents.


Eligibility criteria:
inclusion criteria: * age 13 - 18 * provision of informed assent (or self-consent if age 18) * parent/ guardian consent if under age 18 * regular substance use (use at least 1 per month for past 6 months) exclusion criteria: * active psychosis * mental retardation * neurodevelopmental disorder * severe medical illness

Keywords: motivational interviewing problem drinking adolescents minority health
community-based environmental health intervention

Conditions: Poisoning

Summary: this community-based project, called the together for agricultural safety project, was developed to help farmworkers reduce their exposure to dangerous agricultural chemicals (such as pesticides) through education and social marketing. the project is a partnership of university researchers and the farmworkers association of florida. after collecting extensive data from farmworkers, health providers and farm owners about primary means of pesticide exposure we are collaboratively developing an intervention that will reduce pesticide exposure by educating workers and owners about: the need to have adequate washing facilities; to wash hands frequently; to obey reentry intervals; to change work clothes after work to prevent child exposure and more.


Eligibility criteria:
must be an agricultural worker in the fernery or nursery industries in central florida.

Keywords: pesticide farmworker occupational health
visual stimulation of preterm infants

Conditions: Preterm Infant

Summary: introduction: prematurity rate has increased and is a risk factor for developmental delay. preterm infants with low visual tracking might present deficits in cognition, language, and fine motor function in future ages. few studies applied home stimulation of the visual system for preterm infant (pt) at an early age. objective: to compare the effects of early visual stimulation to a standard care group in visual function, motor and sensory development. methods: randomized controlled trial. at home setting. thirty healthy preterm infants, gestational age from 28 to 37 weeks, aged from one to two months of corrected age at the entrance of the study, with low visual function, will be evaluated. participants will be randomly allocated to: (1) a standard care group, receiving orientation about general sensory and motor development, (2) an early visual stimulation group receiving a 4-week home based protocol applied by caregivers additional to standard care. outcomes will be measured at before the beginning of stimulation, at the end of stimulation and at 6 months of corrected age. primary outcome is visual function evaluated by ml leonhardt battery of optotypes. secondary outcomes include motor and sensory development evaluated by scales.


Eligibility criteria:
inclusion criteria: * gestational age between 28 and 37 weeks * age at enrolment between one to two months of corrected age t * absence of visual impairments evaluated with red reflex examination and complete ophthalmology exam, which will be performed by a doctor at the hospital or the basic health units where the infants will be recruited * infants at home * presence of low acuity assessed by the ml-leonhardt optotypes battery (absence of alertness, fixation and attention in at least three cards, or visual tracking classified as absent or brief for more than three cards) exclusion criteria: * presence of any diagnosed neurological diseases * presence of diagnosed respiratory diseases * hypoxemia, hyperventilation or hypo-ventilation during assessments * presence of congenital diseases * presence of diagnosed visual impairments, such as blindness or low vision * extreme premature, ie, with gestation age bellow 28 weeks due to higher risk of retinopathy of prematurity * birth weight less than 1,000 grams due to higher risk of retinopathy of prematurity * absence of alertness according with precthl and beintema * preterm infant with unstable physiological conditions * preterm infant receiving any kind of intervention such as physical therapy, occupational therapy, early intervention, aquatic stimulation, at the same time that our stimulation protocol is being applied since they can be confounders * infants with medical fragility that prevent them to participate.

Keywords: prematurity sensory stimulation rehabilitation infant